Development of a Cancer Vaccine Using In Vivo Click-Chemistry-Mediated Active Lymph Node Accumulation for Improved Immunotherapy

Development of a Cancer Vaccine Using In Vivo Click-Chemistry-Mediated Active Lymph Node Accumulation for Improved Immunotherapy

© 2021 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 33(2021), 20 vom: 14. Mai, Seite e2006007
1. Verfasser: Qin, Hao (VerfasserIn)
Weitere Verfasser: Zhao, Ruifang, Qin, Yuting, Zhu, Jin, Chen, Long, Di, Chunzhi, Han, Xuexiang, Cheng, Keman, Zhang, Yinlong, Zhao, Ying, Shi, Jian, Anderson, Gregory J, Zhao, Yuliang, Nie, Guangjun
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article cancer vaccines click chemistry immunotherapy lymph node targeting Cancer Vaccines Liposomes Ovalbumin 9006-59-1 Azides mehr... Cyclooctanes Adjuvants, Immunologic
Beschreibung
Zusammenfassung:© 2021 Wiley-VCH GmbH.
Due to their ability to elicit a potent immune reaction with low systemic toxicity, cancer vaccines represent a promising strategy for treating tumors. Considerable effort has been directed toward improving the in vivo efficacy of cancer vaccines, with direct lymph node (LN) targeting being the most promising approach. Here, a click-chemistry-based active LN accumulation system (ALAS) is developed by surface modification of lymphatic endothelial cells with an azide group, which provide targets for dibenzocyclooctyne (DBCO)-modified liposomes, to improve the delivery of encapsulated antigen and adjuvant to LNs. When loading with OVA257-264 peptide and poly(I:C), the formulation elicits an enhanced CD8+ T cell response in vivo, resulting in a much more efficient therapeutic effect and prolonged median survival of mice. Compared to treatment with DBCO-conjugated liposomes (DL)-Ag/Ad without the azide targeting, the percent survival of ALAS-vaccine-treated mice improves by 100% over 60 days. Altogether, the findings indicate that the novel ALAS approach is a powerful strategy to deliver vaccine components to LNs for enhanced antitumor immunity
Beschreibung:Date Completed 24.07.2024
Date Revised 24.07.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202006007